TREMFYA ® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson’s leadership in inflammatory bowel disease
The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA
®
showed highly statistically significant rates of endoscopic remission at one year in the pivotal QUASAR program
1,2,3,4,5
TREMFYA
®
is now...
Zur Pressemeldung auf www.jnj.com